In Wake of Myriad Decision, Some Debate Licensing Models for Gene Patents, While Some Question Value
April 28, 2010
In Wake of Myriad Decision, Some Debate Licensing Models for Gene Patents, While Some Question Value
Since a US federal district court last month deemed seven of Myriad Genetics' BRCA patents invalid, certain industry players have taken small steps toward fostering more collaboration around gene patents while others have raised questions about the value of patenting genes altogether amid rapid advances in whole-genome sequencing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- As Whole-Genome Sequencing Advances, Optimists Find Empowering Knowledge; Others See Dizzying Data
May 12, 2010 / Pharmacogenomics Reporter - Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter - Illumina Partners with DTC Genomics Firms to Offer Whole Genome Sequencing for $48K
June 11, 2009 / GenomeWeb Daily News - Illumina's New DTC Sequencing Service Addresses Ethical Quandary by Requiring Prescription
June 10, 2009 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter